相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
N. Plevris et al.
JOURNAL OF CROHNS & COLITIS (2019)
VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
Stefan Schreiber et al.
JOURNAL OF CROHNS & COLITIS (2019)
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK The REVIVE study
Fraser Cummings et al.
MEDICINE (2019)
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease
Frank I. Scott et al.
INFLAMMATORY BOWEL DISEASES (2019)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Tero Ylisaukko-oja et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists
Martine De Vos et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study
Marco Vincenzo Lenti et al.
DIGESTIVE AND LIVER DISEASE (2018)
DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
S Berends et al.
Journal of Crohns & Colitis (2018)
Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease
Paulo G. Kotze et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
Hang Hock Shim et al.
JGH OPEN (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres
Mark A. Samaan et al.
FRONTLINE GASTROENTEROLOGY (2017)
Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
Christopher Ma et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
A. Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease
W. A. Bye et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Jessica R. Allegretti et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Guidelines for good pharmacoepidemiology practice (GPP)
Elizabeth B. Andrews et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds
Daniel C. Baumgart et al.
PLOS ONE (2016)
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort
Edward Shelton et al.
INFLAMMATORY BOWEL DISEASES (2015)
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease
Lauren N. Cherry et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
